Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management ...

Angiotensin-converting enzyme inhibitors (ACEi) are the leading cause of drug-induced angioedema in the USA, with an ...

The FDA awards Fast Track designation to BW-20805 for hereditary angioedema, a therapy designed to reduce attacks through PKK suppression.

Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedema Epidemiologic data and ...

Pharvaris, a biopharmaceutical company focusing on innovative oral treatments for bradykinin-mediated diseases like hereditary angioedema (HAE), recently shared data from the European Academy of ...

Pharvaris, a late-stage biopharmaceutical company based in Zug, Switzerland, has announced a virtual R&D call titled "Deucrictibant: Beyond HAE Type 1/2" scheduled for June 4, 2025. This event will ...

ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ...

Cold activation of plasma from people living with HAE resulted in increased levels of bradykinin compared to cold-activated plasma of healthy volunteers, resulting in a qualified kinin assay that can ...

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data ...